Skip to main content

Paclitaxel Injection Shortage

Last Updated: January 18, 2024
Status: Current

Products Affected - Description
    • Paclitaxel intravenous solution for injection, Sagent, 100 mg/16.7 mL (6 mg/mL) multiple dose vial, NDC 70860-0200-17
    • Paclitaxel intravenous solution for injection, Sagent, 30 mg/5 mL (6 mg/mL) multiple dose vial, NDC 70860-0200-05
    • Paclitaxel intravenous solution for injection, Teva, 100 mg/16.7 mL (6 mg/mL) multiple dose vial, NDC 00703-3216-01
Reason for the Shortage
    • Almaject has discontinued paclitaxel injection.
    • Fresenius Kabi has paclitaxel injection available. They are no longer marketing the 6 mg/mL 5 mL vials.
    • Pfizer has paclitaxel injection available.
    • Sagent did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
Available Products
    • Paclitaxel intravenous solution for injection, Fresenius Kabi, 100 mg/16.7 mL (6 mg/mL) multiple dose vial, NDC 63323-0763-16
    • Paclitaxel intravenous solution for injection, Fresenius Kabi, 300 mg/50 mL (6 mg/mL) multiple dose vial, NDC 63323-0763-50
    • Paclitaxel intravenous solution for injection, Pfizer, 100 mg/16.7 mL (6 mg/mL) multiple dose vial, NDC 61703-0342-22
    • Paclitaxel intravenous solution for injection, Pfizer, 30 mg/5 mL (6 mg/mL) multiple dose vial, NDC 61703-0342-09
    • Paclitaxel intravenous solution for injection, Pfizer, 300 mg/50 mL (6 mg/mL) multiple dose vial, NDC 61703-0342-50
    • Paclitaxel intravenous solution for injection, Teva, 150 mg/25 mL (6 mg/mL) multiple dose vial, NDC 00703-3217-01
    • Paclitaxel intravenous solution for injection, Teva, 30 mg/5 mL (6 mg/mL) multiple dose vial, NDC 00703-3213-01
    • Paclitaxel intravenous solution for injection, Teva, 300 mg/50 mL (6 mg/mL) multiple dose vial, NDC 00703-3218-01

Estimated Resupply Dates

    • Sagent has paclitaxel 30 mg/5 mL vials and 100 mg/16.7 mL vials on back order and the company cannot estimate a release date.
    • Teva has paclitaxel 100 mg/16.7 mL vials on allocation.

Alternative Agents & Management

    • Consider evaluating the health-care system's total supply of paclitaxel before beginning patients on combination chemotherapy regimens containing paclitaxel. If adequate supplies are not available, select an alternative regimen.
    • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for paclitaxel.
    • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
    • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/policy-guidelines/docs/guidelines/managing-drug-product-shortages.pdf
    • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.

Updated

Updated January 18, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 31, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.